This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1992 Oct 28:660:95-106.

doi: 10.1111/j.1749-6632.1992.tb21062.x.

Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy

J A Zaia¹, S Chatterjee, K K Wong, D Elkins, N R Taylor, J J Rossi

Affiliations

PMID: 1340161
DOI: 10.1111/j.1749-6632.1992.tb21062.x

Review

Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy

J A Zaia et al. Ann N Y Acad Sci. 1992.

. 1992 Oct 28:660:95-106.

doi: 10.1111/j.1749-6632.1992.tb21062.x.

Authors

J A Zaia¹, S Chatterjee, K K Wong, D Elkins, N R Taylor, J J Rossi

Affiliation

¹ Division of Pediatrics, City of Hope National Medical Center, Duarte, California 91010-0269.

PMID: 1340161
DOI: 10.1111/j.1749-6632.1992.tb21062.x

No abstract available

PubMed Disclaimer

Similar articles

Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
Rossi JJ, Sarver N. Rossi JJ, et al. Adv Exp Med Biol. 1992;312:95-109. doi: 10.1007/978-1-4615-3462-4_9. Adv Exp Med Biol. 1992. PMID: 1514448 Review. No abstract available.
A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
Tabler M, Homann M, Tzortzakaki S, Sczakiel G. Tabler M, et al. Nucleic Acids Res. 1994 Sep 25;22(19):3958-65. doi: 10.1093/nar/22.19.3958. Nucleic Acids Res. 1994. PMID: 7937118 Free PMC article.
Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.
Homann M, Tabler M, Tzortzakaki S, Sczakiel G. Homann M, et al. Nucleic Acids Res. 1994 Sep 25;22(19):3951-7. doi: 10.1093/nar/22.19.3951. Nucleic Acids Res. 1994. PMID: 7524030 Free PMC article.
Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy.
Hörster A, Teichmann B, Hormes R, Grimm D, Kleinschmidt J, Sczakiel G. Hörster A, et al. Gene Ther. 1999 Jul;6(7):1231-8. doi: 10.1038/sj.gt.3300955. Gene Ther. 1999. PMID: 10455431
Inhibition of gene expression with ribozymes.
Marschall P, Thomson JB, Eckstein F. Marschall P, et al. Cell Mol Neurobiol. 1994 Oct;14(5):523-38. doi: 10.1007/BF02088835. Cell Mol Neurobiol. 1994. PMID: 7621511 Free PMC article. Review.

See all similar articles

Cited by

New modalities in oncology: ribozymes.
Cunningham CC. Cunningham CC. Proc (Bayl Univ Med Cent). 2002 Jul;15(3):247-9. doi: 10.1080/08998280.2002.11927847. Proc (Bayl Univ Med Cent). 2002. PMID: 16333444 Free PMC article. No abstract available.
Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.
Podsakoff G, Wong KK Jr, Chatterjee S. Podsakoff G, et al. J Virol. 1994 Sep;68(9):5656-66. doi: 10.1128/JVI.68.9.5656-5666.1994. J Virol. 1994. PMID: 8057446 Free PMC article.
Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
Zhou J, Rossi J. Zhou J, et al. J Investig Med. 2014 Oct;62(7):914-9. doi: 10.1097/JIM.0000000000000103. J Investig Med. 2014. PMID: 25118114 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database